Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To demonstrate the efficacy of intranasal fentanyl in the treatment of breakthrough pain
(BTP) in cancer patients.
Secondary Objective:
To explore the relationship between the response to the fentanyl dose and the stable
background pain opioid dose.